Bionomics Inc.

Ironwood Pharmaceuticals, Inc.

Rob Livingston

Bernard Luke Flynn

Andrew John Harvey

Dharam Paul

Song Xue

Ahmad Hashash

Raymond E Forslund

Vasu Sethuraman

The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof. 

Salts, co-crystals, and polymorphs of an anxiolytic compound

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.

Growing community of inventors

Cambridge, MA, United States of America

Rob Livingston